Impact of the new rectal cancer definition on multimodality treatment and interhospital variability: Results from a nationwide cross-sectional study.

التفاصيل البيبلوغرافية
العنوان:	Impact of the new rectal cancer definition on multimodality treatment and interhospital variability: Results from a nationwide cross-sectional study.
المؤلفون:	Hazen SJA; Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., Sluckin TC; Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands., Horsthuis K; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.; Radiology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Lambregts DMJ; Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Beets-Tan RGH; Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; GROW School of Oncology and Developmental Biology, University of Maastricht, Maastricht, The Netherlands., Hompes R; Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, The Netherlands.; Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands., Buffart TE; Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, The Netherlands.; Medical Oncology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Marijnen CAM; Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands., Tanis PJ; Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.; Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.; Surgical Oncology and Gastrointestinal Surgery, Erasmus Medical Center, Rotterdam, The Netherlands., Kusters M; Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
مؤلفون مشاركون:	Dutch Snapshot Research Group
المصدر:	Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland [Colorectal Dis] 2024 Jun; Vol. 26 (6), pp. 1131-1144. Date of Electronic Publication: 2024 Apr 29.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Blackwell Science Ltd Country of Publication: England NLM ID: 100883611 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1318 (Electronic) Linking ISSN: 14628910 NLM ISO Abbreviation: Colorectal Dis Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Oxford, UK : Blackwell Science Ltd.,
مواضيع طبية MeSH:	Rectal Neoplasms/therapy , Rectal Neoplasms/pathology , Rectal Neoplasms/diagnostic imaging , Magnetic Resonance Imaging, Humans ; Cross-Sectional Studies ; Netherlands ; Female ; Male ; Middle Aged ; Aged ; Combined Modality Therapy ; Neoplasm Staging ; Delphi Technique ; Patient Care Team ; Practice Guidelines as Topic ; Clinical Decision-Making/methods
مستخلص:	Aim: This study aimed to determine the consequences of the new definition of rectal cancer for decision-making in multidisciplinary team meetings (MDT). The new definition of rectal cancer, the lower border of the tumour is located below the sigmoid take-off (STO), was implemented in the Dutch guideline in 2019 after an international Delphi consensus meeting to reduce interhospital variations. Method: All patients with rectal cancer according to the local MDT, who underwent resection in 2016 in the Netherlands were eligible for this nationwide collaborative cross-sectional study. MRI-images were rereviewed, and the tumours were classified as above or on/below the STO. Results: This study registered 3107 of the eligible 3178 patients (98%), of which 2784 patients had an evaluable MRI. In 314 patients, the tumour was located above the STO (11%), with interhospital variation between 0% and 36%. Based on TN-stage, 175 reclassified patients with colon cancer (6%) would have received different treatment (e.g., omitting neoadjuvant radiotherapy, candidate for adjuvant chemotherapy). Tumour location above the STO was independently associated with lower risk of 4-year locoregional recurrence (HR 0.529; p = 0.030) and higher 4-year overall survival (HR 0.732; p = 0.037) compared to location under the STO. Conclusion: By using the STO, 11% of the prior MDT-based diagnosis of rectal cancer were redefined as sigmoid cancer, with potential implications for multimodality treatment and prognostic value. Given the substantial interhospital variation in proportion of redefined cancers, the use of the STO will contribute to standardisation and comparability of outcomes in both daily practice and trial settings. (© 2024 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.)
References:	D'Souza N, de Neree Tot Babberich MPM, Lord A, Shaw A, Abulafi M, Tekkis P, et al. The rectosigmoid problem. Surg Oncol. 2018;27(3):521–525. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta‐analysis of individual patient data. Lancet Oncol. 2015;16(2):200–207. André T, Boni C, Mounedji‐Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–646. Bujko K, Nowacki MP, Nasierowska‐Guttmejer A, Michalski W, Bebenek M, Kryj M. Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–1223. D'Souza N, de Neree Tot Babberich MPM, d'Hoore A, Tiret E, Xynos E, Beets‐Tan R, et al. Definition of the rectum: an international, expert‐based Delphi consensus. Ann Surg. 2019;270(6):955–959. Available from: https://richtlijnendatabase.nl/richtlijn/colorectaal_carcinoom_crc/diagnostiek_bij_crc/locoregionale_stadi_ring_rectumcarcinoom.html. [accessed 15‐12‐2022]. Glynne‐Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2018;29(Suppl 4):iv263. You YN, Hardiman KM, Bafford A, Poylin V, Francone TD, Davis K, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer. Dis Colon Rectum. 2020;63(9):1191–1222. Benson AB, Venook AP, Al‐Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Cancer Netw. 2020;18(7):806–815. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42. Li F, Wang B, Lu S, Wang Y, Sun T, Wang H, et al. Comparison of the sigmoid take‐off with other definitions of the rectosigmoid junction: a retrospective comparative cohort analysis. Int J Surg. 2020;80:168–174. Van Leersum NJ, Snijders HS, Henneman D, Kolfschoten NE, Gooiker GA, ten Berge MG, et al. The Dutch surgical colorectal audit. Eur J Surg Oncol. 2013;39(10):1063–1070. Group DSR. Benchmarking recent national practice in rectal cancer treatment with landmark randomized controlled trials. Color Dis. 2017;19(6):O219–O231. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. Glimelius B, Tiret E, Cervantes A, Arnold D. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2013;24 Suppl 6:vi81–vi88. Hazen SJA, Sluckin TC, Horsthuis K, Lambregts DMJ, Beets‐Tan RGH, Tanis PJ, et al. Evaluation of the implementation of the sigmoid take‐off landmark in The Netherlands. Color Dis. 2021;24:292–307. Available from: https://richtlijnendatabase.nl/richtlijn/colorectaal_carcinoom_crc/primaire_behandeling_rectumcarcinoom_bij_crc.html. 2019 [accessed 15‐12‐2022]. National Institute for Health and Care Excellence. Colorectal cancer. National Institute for Health and Care Excellence: Guidelines. London: NICE Copyright © NICE 2021; 2021. Lakkis Z, Manceau G, Bridoux V, Brouquet A, Kirzin S, Maggiori L, et al. Management of rectal cancer: the 2016 French guidelines. Color Dis. 2017;19(2):115–122. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow‐up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693–701. Iversen H, Martling A, Johansson H, Nilsson PJ, Holm T. Pelvic local recurrence from colorectal cancer: surgical challenge with changing preconditions. Color Dis. 2018;20(5):399–406. Ogura A, Konishi T, Cunningham C, Garcia‐Aguilar J, Iversen H, Toda S, et al. Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol. 2019;37(1):33–43. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EMK, et al. Short‐course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open‐label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42. Detering R, Karthaus EG, Borstlap WAA, Marijnen CAM, van de Velde CJH, Bemelman WA, et al. Treatment and survival of locally recurrent rectal cancer: a cross‐sectional population study 15 years after the Dutch TME trial. Eur J Surg Oncol. 2019;45(11):2059–2069. Kusters M, Dresen RC, Martijn H, Nieuwenhuijzen GA, van de Velde CJH, van den Berg HA, et al. Radicality of resection and survival after multimodality treatment is influenced by subsite of locally recurrent rectal cancer. Int J Radiat Oncol Biol Phys. 2009;75(5):1444–1449. Hagemans JAW, van Rees JM, Alberda WJ, Rothbarth J, Nuyttens JJME, van Meerten E, et al. Locally recurrent rectal cancer; long‐term outcome of curative surgical and non‐surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol. 2020;46(3):448–454. Falch C, Mueller S, Braun M, Gani C, Fend F, Koenigsrainer A, et al. Oncological outcome of carcinomas in the rectosigmoid junction compared to the upper rectum or sigmoid colon – a retrospective cohort study. Eur J Surg Oncol. 2019;45(11):2037–2044. Käser SA, Froelicher J, Li Q, Müller S, Metzger U, Castiglione M, et al. Adenocarcinomas of the upper third of the rectum and the rectosigmoid junction seem to have similar prognosis as colon cancers even without radiotherapy, SAKK 40/87. Langenbeck's Arch Surg. 2015;400(6):675–682. Lee YC, Lee YL, Chuang JP, Lee JC. Differences in survival between colon and rectal cancer from SEER data. PLoS One. 2013;8(11):e78709. Mukai M, Kishima K, Yamazaki M, Aoki H, Izumi H, Yamamoto S, et al. Stage II/III cancer of the rectosigmoid junction: an independent tumor type? Oncol Rep. 2011;26(3):737–741. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Different patterns of lymphatic spread of sigmoid, rectosigmoid, and rectal cancers. Ann Surg Oncol. 2008;15(12):3478–3483. Bogveradze N, Lambregts DMJ, El Khababi N, Dresen RC, Maas M, Kusters M, et al. The sigmoid take‐off as a landmark to distinguish rectal from sigmoid tumours on MRI: reproducibility, pitfalls and potential impact on treatment stratification. Eur J Surg Oncol. 2022;48(1):237–244. Chaves MM, Donato H, Campos N, Silva D, Curvo‐Semedo L. Interobserver variability in MRI measurements of mesorectal invasion depth in rectal cancer. Abdom Radiol (NY). 2022;47(3):907–914. Kilickap G, Dolek BA, Ercan K. Intra‐ and interobserver agreement of rectal cancer staging with MRI. Acta Radiol. 2023;64(5):1747–1754.
معلومات مُعتمدة:	KWF Kankerbestrijding; 12768 Dutch Cancer Society (KWF)
فهرسة مساهمة:	Investigator: AGJ Aalbers; SM van Aalten; FJ Amelung; M Ankersmit; IE Antonisse; JF Ashruf; TS Aukema; H Avenarius; RR Bahadoer; FCH Bakers; IS Bakker; F Bangert; RM Barendse; HMD Beekhuis; GL Beets; WA Bemelman; M Berbée; SH de Bie; RHC Bisschops; LW van Bockel; AH Boer; FC den Boer; EG Boerma; LSF Boogerd; J Borstlap; WAA Borstlap; RD Blok; JE Bouwman; SJ Braak; MNGJA Braat; J Bradshaw; ATA Brandsma; V van Breest Smallenburg; WT van den Broek; SW van der Burg; JWA Burger; TA Burghgraef; DWG Ten Cate; HM Ceha; JS Cnossen; RJ Coebergh van den Braak; ECJ Consten; M Corver; RMPH Crolla; S Curutchet; AW Daniëls-Gooszen; PHP Davids; EN Dekker; JWT Dekker; A Demirkiran; T Derksen; AL Diederik; AM Dinaux; K Dogan; IM van Dop; KE Droogh-de Greve; H Duijsens; MS Dunker; J Duyck; EB van Duyn; LSE van Egdom; B Eijlers; Y El-Massoudi; S van Elderen; AMLH Emmen; M Engelbrecht; AC van Erp; JA van Essen; HFJ Fabry; T Fassaert; EA Feitsma; SS Feshtali; B Frietman; EJB Furnée; A van Geel; ED Geijsen; N van Geloven; MF Gerhards; H Gielkens; R van Gils; L Goense; MJPM Govaert; WMU van Grevenstein; EJ de Groof; I de Groot; RJ de Haas; NAG Hakkenbrak; MD den Hartogh; V Heesink; JT Heikens; EM Hendriksen; S van den Hoek; EJRJ van der Hoeven; C Hoff; A Hogewoning; CRC Hogewoning; S Hoogendoorn; F van Hoorn; RL van der Hul; R van Hulst; F Imani; B Inberg; MPW Intven; P Janssen; CEJ de Jong; J Jonkers; D Jou-Valencia; B Keizers; SHJ Ketelaers; E Knöps; S van Koeverden; S Kok; SEM Kolderman; FI de Korte; RTJ Kortekaas; JC Korving; IM Koster; J Krdzalic; P Krielen; LF Kroese; E Krul; D Lahuis; B Lamme; AAG van Landeghem; JWA Leijtens; MM Leseman-Hoogenboom; M de Lijster; MS Marsman; MH Martens; I Masselink; W van der Meij; P Meijnen; J Melenhorst; DJL de Mey; J Moelker-Galuzina; L Morsink; EJ Mulder; K Muller; GD Musters; J Nederend; PA Neijenhuis; LCF de Nes; M Nielen; JBJ van den Nieuwboer; JF Nieuwenhuis; J Nonner; BJ Noordman; S Nordkamp; PB Olthof; SJ Oosterling; D Ootes; V Oppedijk; P Ott; I Paulusma; KCMJ Peeters; ITA Pereboom; J Peringa; Z Pironet; JDJ Plate; F Polat; IGM Poodt; LAE Posma; JF Prette; BB Pultrum; SM Qaderi; JM van Rees; RJ Renger; AJM Rombouts; L Roosen; EA Roskott-Ten Brinke; J Rothbarth; DB Rouw; T Rozema; H Rutten; HJT Rutten; ME van der Sande; BE Schaafsma; RA Schasfoort; MM Scheurkogel; AP Schouten van der Velden; WH Schreurs; PME Schuivens; C Sietses; PCG Simons; MJ Slob; GD Slooter; M van der Sluis; BP Smalbroek; AB Smits; EJ Spillenaar-Bilgen; PH Spruit; TC Stam; J Stoker; AK Talsma; S Temmink; GYM The; JAW Tielbeek; AAJM van Tilborg; F van Tilborg; D van Trier; JB Tuynman; MJM van der Valk; IJS Vanhooymissen; GBC Vasbinder; CJ Veeken; LA Velema; AWH van de Ven; EGG Verdaasdonk; WM Verduin; T Verhagen; PM Verheijen; M Vermaas; AE Verrijssen; AVD Verschuur; HV Schaik; RFA Vliegen; S Voets; FJ Vogelaar; CLA Vogelij; HA Vos-Westerman; M de Vries; JC Vroemen; BST van Vugt; JA Wegdam; BJ van Wely; M Westerterp; PP van Westerveld; HL van Westreenen; AG Wijma; JHW de Wilt; BWK de Wit; F Wit; K Woensdregt; V van Woerden; FSW van der Wolf; S van der Wolk; JM Wybenga; ES van der Zaag; B Zamaray; HJA Zandvoort; D van der Zee; A Zeilstra; KJ Zheng; DDE Zimmerman; M Zorgdrager Keywords: rectal cancer; rectosigmoid; sigmoid cancer; sigmoid take‐off; treatment
تواريخ الأحداث:	Date Created: 20240429 Date Completed: 20240627 Latest Revision: 20240627
رمز التحديث:	20240627
DOI:	10.1111/codi.17002
PMID:	38682286
قاعدة البيانات:	MEDLINE

View record at Wiley

Full Text Finder

الوصف
تدمد:	1463-1318
DOI:	10.1111/codi.17002